Analytical aspects of molecular Alzheimers disease biomarkers

Biomarkers in Medicine

Volumn 6, Issue 4, 2012, Pages 377-389

  Andreasson, Ulf ^a   Vanmechelen, Eugeen ^b   Shaw, Leslie M ^c   Zetterberg, Henrik ^a,d,e   Vanderstichele, Hugo ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ADX NEUROSCIENCES   (Belgium)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

accuracy; Alzheimers disease; biomarkers; cerebrospinal fluid; pathophysiology; quality control

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ALZHEIMER DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LABORATORY TEST; MASS SPECTROMETRY; NEUROIMAGING; NEUROPATHOLOGY; PATIENT MONITORING; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUALITY CONTROL; REFERENCE VALUE; REVIEW; SELECTED REACTION MONITORING; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; PEPTIDE FRAGMENTS; PHOSPHORYLATION; QUALITY CONTROL; TAU PROTEINS;

EID: 84865508067     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.44     Document Type: Review

References (63)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
2. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1(2), 189-195 (2004). (Pubitemid 46604746)
3. Lee JW, Weiner RS, Sailstad JM et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res. 22(4), 499-511 (2005). (Pubitemid 40603246)
4. Mattsson N, Zegers I, Andreasson U et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid b42. Biomarkers Med. 6(4), 409-417 (2012).
5. Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease'. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 19(2), 109-116 (1998).
6. Mueller SG, Weiner MW, Thal LJ et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 1(1), 55-66 (2005). (Pubitemid 43348857)
7. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov. 6(4), 295-303 (2007). (Pubitemid 46505880)
8. Anoop A, Singh PK, Jacob RS, Maji SK. CSF biomarkers for Alzheimer's disease diagnosis. Int. J. Alzheimers Dis. 2010, pii 606802 (2010).
9. Zetterberg H. New diagnostic criteria for Alzheimer's disease. Biomark. Med. 5(4), 407-409 (2011).
10. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 6(2), 67-77 (2010).
11. Laforce R Jr, Rabinovici GD. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res. Ther. 3(6), 31 (2011).
12. Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden - regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. Eur. Neuropsychopharmacol. 21(11), 781-788 (2011).
13. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120(3), 885-890 (1984). First report on the sequence of the ß-amyloid peptide isolated from the human brain. (Pubitemid 14104991)
14. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82(12), 4245-4249 (1985). (Pubitemid 15053619)
15. Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325(6106), 733-736 (1987). (Pubitemid 17054046)
16. Seubert P, Vigo-Pelfrey C, Esch F et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359(6393), 325-327 (1992). The prescence of Ab in human cerebrospinal fluid (CSF) was established.
17. Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem. Biophys. Res. Commun. 200(3), 1598-1603 (1994).
18. van Gool WA, Kuiper MA, Walstra GJ, Wolters EC, Bolhuis PA. Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 37(2), 277-279 (1995).
19. Southwick PC, Yamagata SK, Echols CL Jr et al. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J. Neurochem. 66(1), 259-265 (1996). (Pubitemid 26010789)
20. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitationmass spectrometry. J. Proteome Res. 5(4), 1010-1016 (2006).
21. Motter R, Vigo-Pelfrey C, Kholodenko D et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38(4), 643-648 (1995). First evidence that ß-amyloid 1-42 is lower in cerebrospinal fluid (CSF) from Alzheimer's disease (AD) patients.
22. Bjerke M, Portelius E, Minthon L et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int. J. Alzheimers Dis. 2010, pii 986310 (2010).
23. Sergeant N, Bombois S, Ghestem A et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem. 85(6), 1581-1591 (2003). (Pubitemid 36702570)
24. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc. Natl Acad. Sci. USA 72(5), 1858-1862 (1975).
25. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83(13), 4913-4917 (1986). Identification of phosphorylated-tau in neurofibrillary tangles.
26. Vandermeeren M, Mercken M, Vanmechelen E et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61(5), 1828-1834 (1993). First evidence that total-tau is higher in CSF from AD patients. (Pubitemid 23317209)
27. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26(3), 231-245 (1995). First evidence that phosphorylated-tau is higher in CSF from AD patients. (Pubitemid 26002016)
28. Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 52(8), 1555-1562 (1999). (Pubitemid 29220627)
29. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5(3), 228-234 (2006). (Pubitemid 43238346)
30. Vanderstichele H, De Vreese K, Blennow K et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin. Chem. Lab. Med. 44(12), 1472-1480 (2006). (Pubitemid 44967698)
31. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 90(2), 465-494 (2010).
32. Mattsson N, Andreasson U, Persson S et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7(4), 386-395.e6 (2011).
33. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1(2), 213-225 (2004). (Pubitemid 46589353)
34. Sjogren M, Davidsson P, Tullberg M et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 70(5), 624-630 (2001). (Pubitemid 32397998)
35. Buerger K, Zinkowski R, Teipel SJ et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 59(8), 1267-1272 (2002). (Pubitemid 34856379)
36. Hu WT, Chen-Plotkin A, Arnold SE et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 119(6), 669-678 (2010).
37. Öhrfelt A, Andreasson U, Simon AJ et al. Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. Extra 1, 31-42 (2011).
38. Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13(11), 1359-1362 (2007). (Pubitemid 350073592)
39. O'Bryant SE, Xiao G, Barber R et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch. Neurol. 67(9), 1077-1081 (2010).
40. Rye PD, Booij BB, Grave G et al. A novel blood test for the early detection of Alzheimer's disease. J. Alzheimers Dis. 23(1), 121-129 (2011).
41. Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D et al. Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression. Alzheimers Dement. 6(1), 25-38 (2010).
42. Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4), 385-393 (2009).
43. Mulder C, Verwey NA, van der Flier WM et al. Amyloid-beta (1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem. 56(2), 248-253 (2010).
44. Engwall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G. Immunochemistry 8, 871-874 (1971).
45. Van Weemen BK, Schuurs AH. Immunoassay using antigen-enzyme conjugates. FEBS Lett. 15(3), 232-236 (1971).
46. Forster RJ, Bertoncello P, Keyes TE. Electrogenerated chemiluminescence. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 2, 359-385 (2009).
47. Bielefeld-Sevigny M. AlphaLISA immunoassay platform - the no-wash' high-throughput alternative to ELISA. Assay Drug Dev. Technol. 7(1), 90-92 (2009).
48. Portelius E, Zetterberg H, Andreasson U et al. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci. Lett. 409(3), 215-219 (2006). (Pubitemid 44648565)
49. Oe T, Ackermann BL, Inoue K et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20(24), 3723-3735 (2006). (Pubitemid 44935325)
50. Gelfanova V, Higgs RE, Dean RA et al. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-TOF mass spectrometry. Brief. Funct. Genomic Proteomic 6(2), 149-158 (2007). (Pubitemid 351721078)
51. Verpillot R, Essellmann H, Mohamadi MR et al. Analysis of amyloid-beta peptides in cerebrospinal fluid samples by capillary electrophoresis coupled with LIF detection. Anal. Chem. 83(5), 1696-1703 (2011).
52. Lame ME, Chambers EE, Blatnik M. Quantitation of amyloid beta peptides Abeta (1-38), Abeta (1-40), and Abeta (1-42) in human cerebrospinal fluid by ultraperformance liquid chromatography-tandem mass spectrometry. Anal. Biochem. 419(2), 133-139 (2011). Proof-of-principle for using selected reaction monitoring for quantitative amyloid-b measurements in human CSF.
53. Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on 389 www.futuremedicine.com tubulin polymerization. EMBO J. 9(13), 4225-4230 (1990). (Pubitemid 120025977)
54. Portelius E, Hansson SF, Tran AJ et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J. Proteome Res. 7(5), 2114-2120 (2008).
55. Ray CA, Bowsher RR, Smith WC et al. Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. J. Pharm. Biomed. Anal. 36(5), 1037-1044 (2005). (Pubitemid 40037824)
56. Vanderstichele H, De Meyer G, Shapiro F et al. Alzheimer's disease biomarkers: from concept to clinical utility. In: BioMarkers for Early Diagnosis of Alzheimer's Disease. Galimberti D, Scarpini E (Eds). Nova Science Publishers, NY, USA 81-122 (2008).
57. Wood WG. Matrix effects' in immunoassays. Scand. J. Clin. Lab. Invest. Suppl. 205, 105-112 (1991).
58. Vanderstichele H, Van Kerschaver E, Hesse C et al. Standardization of measurement of beta-amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid 7(4), 245-258 (2000).
59. Williams JH, Wilcock GK, Seeburger J et al. Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study. Alzheimers Res. Ther. 3(1), 5 (2011).
60. Olsson A, Vanderstichele H, Andreasen N et al. Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51(2), 336-345 (2005). (Pubitemid 40175803)
61. Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid beta (1-42), tau, and phosphorylated tau in Alzheimer's disease: report of an international workshop. Int. J. Alzheimers Dis. 2010, pii 635053 (2010).
62. Vanderstichele H, Bibl M, Engelborghs S et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 8(1), 65-73 (2012).
63. Perret-Liaudet A, Pelpel M, Tholance Y et al. Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Clin. Chem. 58(4), 787-789 (2012)... Website 101 The Alzheimer's Association QC program for CSF biomarkers. http://neurochem.gu.se/TheAlzAssQCProgram